This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-12. Anything still debated is marked as such rather than presented as settled.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
=== Biomaterials === Hydrogels are three-dimensional network structures with high hydrophilicity that can absorb and retain large amounts of water. Due to their excellent biocompatibility, they are widely used in the field of biomaterials. The main feature of hydrogels is their high water content, which is similar to the aqueous environment in biological systems, making them ideal for applications in tissue engineering, drug delivery, wound dressings, and artificial skin. Hydrogels can be classified into natural and synthetic types. Natural hydrogels, such as gelatin and chitosan, are derived from biological materials and offer good biodegradability and biocompatibility. Synthetic hydrogels, on the other hand, typically have higher mechanical strength and tunability but may exhibit lower biocompatibility. Additionally, hydrogels can be categorized as environmental-responsive or non-responsive based on their response to external stimuli. Environmental-responsive hydrogels, which can react to changes in temperature, pH, or ion concentration, are particularly useful in drug delivery systems. Due to their tunability, hydrogels continue to expand their applications in the biomedical field and are expected to play a crucial role in various medical applications in the future. Implanted or injected hydrogels have the potential to support tissue regeneration by mechanical tissue support, localized drug or cell delivery, local cell recruitement or immunomodulation, or encapsulation of nanoparticles for local photothermal therapy or brachytherapy.
== Paralogy == Paralogous genes are genes that are related via duplication events in the last common ancestor (LCA) of the species being compared. They result from the mutation of duplicated genes during separate speciation events. When descendants from the LCA share mutated homologs of the original duplicated genes then those genes are considered paralogs. As an example, in the LCA, one gene (gene A) may get duplicated to make a separate similar gene (gene B), those two genes will continue to get passed to subsequent generations. During speciation, one environment will favor a mutation in gene A (gene A1), producing a new species with genes A1 and B. Then in a separate speciation event, one environment will favor a mutation in gene B (gene B1) giving rise to a new species with genes A and B1. The descendants' genes A1 and B1 are paralogous to each other because they are homologs that are related via a duplication event in the last common ancestor of the two species. Additional classifications of paralogs include alloparalogs (out-paralogs) and symparalogs (in-paralogs). Alloparalogs are paralogs that evolved from gene duplications that preceded the given speciation event. In other words, alloparalogs are paralogs that evolved from duplication events that happened in the LCA of the organisms being compared. The example above is an example alloparalogy. Symparalogs are paralogs that evolved from gene duplication of paralogous genes in subsequent speciation events.
Because this process removes/inactivates the lipid coating of a virus, viruses without any sort of lipid envelope will be unaffected. There is also no inactivation effect by the buffers used in this process.
=== Hypnotic === Chloral hydrate has not been approved by the FDA in the United States nor the EMA in the European Union for any medical indication and is on the FDA list of unapproved drugs that are still prescribed by clinicians. Usage of the drug as a sedative or hypnotic may carry some risk given the lack of clinical trials. However, chloral hydrate products, licensed for short-term management of severe insomnia, are available in the United Kingdom. Chloral hydrate was voluntarily removed from the market by all manufacturers in the United States in 2012. Prior to that, chloral hydrate may have been sold as a "legacy" or "grandfathered" drug; that is, a drug that existed prior to the time certain FDA regulations took effect and therefore, some pharmaceutical companies have argued, has never required FDA approval. New drugs did not have to be approved for safety until Congress passed the Federal Food, Drug, and Cosmetic Act (the "FD&C Act") in 1938. Further, a new drug did not have to be proven effective until 1962, when Congress amended the Act. Manufacturers contend that such "legacy drugs", by virtue of the fact that they have been prescribed for decades, have gained a history of safety and efficacy. Chloral hydrate was used for the short-term treatment of insomnia and as a sedative before minor medical or dental treatment. It was largely displaced in the mid-20th century by barbiturates and subsequently by benzodiazepines.
Sources: en.wikipedia.org
Conversely, of the 251 known stable nuclides, only five have both an odd number of protons and odd number of neutrons: hydrogen-2 (deuterium), lithium-6, boron-10, nitrogen-14, and tantalum-180m. Also, only four naturally occurring, radioactive odd–odd nuclides have a half-life >109 years: potassium-40, vanadium-50, lanthanum-138, and lutetium-176. Odd–odd primordial nuclides are rare because most odd–odd nuclei beta-decay, because the decay products are even–even, and are therefore more strongly bound, due to nuclear pairing effects. Yet another effect of the instability of an odd number of either type of nucleon is that odd-numbered elements tend to have fewer stable isotopes. Of the 26 monoisotopic elements (those with only one stable isotope), all but one have an odd atomic number, and all but one has an even number of neutrons: the single exception to both rules is beryllium. The end of the stable elements occurs after lead, largely because nuclei with 128 neutrons—two neutrons above the magic number 126—are extraordinarily unstable and almost immediately alpha-decay. This contributes to the very short half-lives of astatine, radon, and francium. A similar phenomenon occurs to a much lesser extent with 84 neutrons—two neutrons above the magic number 82—where various isotopes of lanthanide elements alpha-decay.
As of 2025, many companies are researching and manufacturing new insulin analogues. These insulins are usually designed to be either ultra-short-acting or ultra-long-acting. Insulin degludec, an ultra-long-acting insulin analog, was developed by Novo Nordisk and approved by the FDA in 2015. Insulin degludec has an extended duration of action, lasting up to 42 hours, offering greater flexibility in dosing schedules. In March 2024, insulin icodec was approved for medical use in Canada. The same month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion, recommending the granting of marketing authorization for Awiqli, under which insulin icodec is marketed. Following the CHMP's recommendation, insulin icodec was approved for medical use in the European Union in May 2024. Insulin icodec has a plasma half-life more than eight days (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.
=== Reassigned Codon Behavior === When codon reassignment occurs, it is usually due to a change in tRNAs. A tRNA can be assigned to a new codon or the tRNA can be altered to pick up a different amino acid. For the protein, this means either swapping one amino acid for another, or in the case of a stop codon, adding an amino acid where there was none before. Since the primary structure determines the functionality of a protein, changing even one amino acid in this way can drastically impact what the final protein is able to do.
Gunston, Bill. An Illustrated Guide to Allied Fighters of World War II. London: Salamander Books Ltd, 1981. ISBN 0-668-05228-7. Gunston, Bill. Aerei della seconda guerra mondiale (in Italian). Milan: Peruzzo editore, 1984. No ISBN. Gunston, Bill and Mike Spick. Modern Air Combat. Crescent Books, 1983, ISBN 91-972803-8-0. Gunston, Bill. North American P-51 Mustang. New York: Gallery Books, 1990. ISBN 0-8317-1402-6. Gunston, Bill and Robert F. Dorr. "North American P-51 Mustang: The Fighter That Won the War." Wings of Fame, Volume 1. London: Aerospace, 1995, pp. 56–115. ISBN 1-874023-74-3. Hagedorn, Dan. Central American and Caribbean Air Forces. Tonbridge, Kent, UK: Air-Britain (Historians), 1993. ISBN 0-85130-210-6. Hagedorn, Dan. Latin American Air Wars & Aircraft. Crowborough, UK: Hikoki, 2006. ISBN 1-902109-44-9. Hammond, Grant. The Mind of War: John Boyd and American Security, Smithsonian Institution Press, 2001, ISBN 1-56098-941-6. Hastings, Max. Bomber Command. Minneapolis, Minnesota: Zenith Press, 1979. ISBN 978-0-76034-520-7. Hatch, Gardner N.; Winter, Frank H. (1993). P-51 Mustang. Paducah, KY: Turner Publishing Company. ISBN 978-1-56311-080-1. Hess, William N. Fighting Mustang: The Chronicle of the P-51. New York: Doubleday and Company, 1970. ISBN 0-912173-04-1. "History, Boeing: P-51 Mustang". Boeing. Retrieved: 24 June 2014. Jackson, Robert. Aircraft of World War II: Development, Weaponry, Specifications. Edison, New Jersey: Chartwell Books, 2003. ISBN 0-7858-1696-8. Jackson, Robert. Mustang: The Operational Record.
Divalent (or bivalent) single-chain variable fragments (di-scFvs, bi-scFvs) can be engineered by linking two scFvs. This can be done by producing a single peptide chain with two VH and two VL regions, yielding tandem scFvs. Another possibility is the creation of scFvs with linker peptides that are too short for the two variable regions to fold together (about five amino acids), forcing scFvs to dimerize. This type is known as diabodies. Diabodies have been shown to have dissociation constants up to 40-fold lower than corresponding scFvs, meaning that they have a much higher affinity to their target. Consequently, diabody drugs could be dosed much lower than other therapeutic antibodies and are capable of highly specific targeting of tumors in vivo. Still shorter linkers (one or two amino acids) lead to the formation of trimers, so-called triabodies or tribodies. Tetrabodies have also been produced. They exhibit an even higher affinity to their targets than diabodies. All of these formats can be composed from variable fragments with specificity for two different antigens, in which case they are types of bispecific antibodies. The furthest developed of these are bispecific tandem di-scFvs, known as bi-specific T-cell engagers (BiTE antibody constructs).
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.